Insider · CIK 0001864793
Rajesh Krishnan
Files at ONCT (Oncternal Therapeutics, Inc.). First filing -, latest -.
In brief
Rajesh Krishnan files SEC Form 4 as officer at ONCT (Oncternal Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Rajesh Krishnan has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 14, 2024 | ONCT Oncternal Therapeutics, Inc. | AGrant or award Stock Optionderivative | +17,700 | $0.00 | $0 | 17,700 | Feb 15, 2024 |
| Jan 3, 2024 | ONCT Oncternal Therapeutics, Inc. | FTax withholding Common Stock | -11,838 | $0.50 | $5,873 | 44,019 | Jan 5, 2024 |
| Feb 21, 2023 | ONCT Oncternal Therapeutics, Inc. | AGrant or award Stock Optionderivative | +220,000 | $0.00 | $0 | 220,000 | Feb 23, 2023 |
| Jan 3, 2023 | ONCT Oncternal Therapeutics, Inc. | FTax withholding Common Stock | -6,238 | $1.02 | $6,363 | 66,754 | Jan 5, 2023 |
Questions about Rajesh Krishnan
Answered from the filings on this page, as of the latest one.
Is Rajesh Krishnan buying or selling?
Rajesh Krishnan has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Rajesh Krishnan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rajesh Krishnan has 0.
Where does Rajesh Krishnan file Form 4?
Rajesh Krishnan has filed Form 4 at ONCT (Oncternal Therapeutics, Inc.) as Chief Technology Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.